Q38879138 | 1,25-Dihydroxyvitamin D as Monotherapy for XLH: Back to the Future? |
Q30428653 | A Genetic Murine Model of Endolymphatic Hydrops: The Phex Mouse |
Q39074268 | A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice |
Q35783146 | A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells |
Q51308109 | A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. |
Q27690863 | A unified model for bone-renal mineral and energy metabolism |
Q82680331 | Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets |
Q34632352 | Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation |
Q35869678 | Approach to the hypophosphatemic patient |
Q36515176 | CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders |
Q48314203 | Cinacalcet as an alternative to phosphate therapy in X-linked hypophosphataemic rickets. |
Q34262497 | Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status |
Q36129867 | Conventional Therapy in Adults With XLH Improves Dental Manifestations, But Not Enthesopathy |
Q37801814 | Disorders of phosphorus homeostasis |
Q47180546 | Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets |
Q48316515 | Evaluation of a New Fully Automated Assay for Plasma Intact FGF23. |
Q35073296 | Evaluation of hypophosphatemia: lessons from patients with genetic disorders. |
Q90624325 | FGF23 and Associated Disorders of Phosphate Wasting |
Q64040255 | FGF23 and its role in X-linked hypophosphatemia-related morbidity |
Q37806136 | Familial hypophosphatemia: an unusual presentation with low back ache, heel pain, and a limp in a young man, and literature review |
Q55364455 | Fibroblast Growth Factor 2 and Its Receptors in Bone Biology and Disease. |
Q36067879 | Fibroblast growth factor 23 and Inflammation in CKD |
Q36360389 | Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications |
Q56627579 | Hypophosphatemic rickets |
Q34069793 | Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis |
Q38045788 | Hypophosphatemic rickets: unraveling the role of FGF23. |
Q47760764 | Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice |
Q37592511 | Iron and fibroblast growth factor 23 in X-linked hypophosphatemia |
Q57736114 | Magnetic Resonance Imaging Features as Surrogate Markers of X-Linked Hypophosphatemic Rickets Activity |
Q39720272 | Oncogenic osteomalacia illustrating the effect of fibroblast growth factor 23 on phosphate homeostasis |
Q35860672 | Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. |
Q26860470 | Regulation and function of the FGF23/klotho endocrine pathways |
Q27026805 | Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway |
Q41119964 | Results of deformity correction in children with X-linked hereditary hypophosphatemic rickets by external fixation or combined technique |
Q85036605 | Rickets |
Q89703178 | Rickets |
Q46294748 | Skeletal mineralization defects in adult hypophosphatasia--a clinical and histological analysis. |
Q53695740 | The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine. |
Q34221238 | The changing face of hypophosphatemic disorders in the FGF-23 era |
Q36074718 | The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled |
Q36318290 | The consequences of chronic kidney disease on bone metabolism and growth in children |
Q37648693 | Therapeutic management of hypophosphatemic rickets from infancy to adulthood. |
Q34786125 | Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability. |
Q41977160 | Three-year successful cinacalcet treatment of secondary hyperparathyroidism in a patient with x-linked dominant hypophosphatemic rickets: a case report |
Q37107383 | Treatment of Hypophosphatemic Rickets with Phosphate and Active Vitamin D in Japan: A Questionnaire-based Survey |
Q46711944 | Treatment of ear and bone disease in the Phex mouse mutant with dietary supplementation. |
Q33952501 | Vitamin D status and bone and connective tissue turnover in brown bears (Ursus arctos) during hibernation and the active state |
Q37056389 | What's new in FGF23 research? |
Q39107200 | X-linked hypophosphatemia and growth. |
Search more.